Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IAV-OX40L
- Development stage
- Preclinical
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
IAV-OX40L is a genetically engineered **chimeric oncolytic influenza A virus** that has been modified to express the **OX40 ligand (OX40L) gene** within its nonstructural (NS1) protein gene. This modification enables the virus to deliver OX40L to tumor microenvironments upon infection. The mechanism of action leverages both the cytolytic properties of the influenza virus and the immune-activating effects of OX40L; the latter augments antitumor immunity by **stimulating Th1-dominant immune responses**, increasing the activation and proliferation of **CD4+ and CD8+ T cells**, and enhancing the secretion of interferon-γ and interleukin-2. In preclinical models of hepatocellular carcinoma (HCC), IAV-OX40L demonstrated selective cytotoxicity for tumor cells and significant tumor inhibition in mice with minimal impact on normal tissues. The therapy is being investigated as a novel virotherapy platform for treating cancers, specifically liver cancer[5].
- Brand names
- IAV-OX40LIAV-OX-40LIAV-OX 40L
- Other names
- IAV-OX40LIAV-OX-40LIAV-OX 40L
02
Targets
CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on IAV-OX40L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IAV-OX40L.